Australia Approves Shorter Mavenclad Treatment Regimen for Relapsing-Remitting MS
News
Australia has approved a shorter treatment regimen of Merck’s Mavenclad for relapsing-remitting multiple sclerosis.
The Therapeutic Goods Administration authorized 20-day courses of the cladribine tablet form of the medication once ... Read more